NO310653B1 - Nye arylalkyl(tio)karboksamider, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem - Google Patents
Nye arylalkyl(tio)karboksamider, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem Download PDFInfo
- Publication number
- NO310653B1 NO310653B1 NO19962208A NO962208A NO310653B1 NO 310653 B1 NO310653 B1 NO 310653B1 NO 19962208 A NO19962208 A NO 19962208A NO 962208 A NO962208 A NO 962208A NO 310653 B1 NO310653 B1 NO 310653B1
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compound
- compounds
- naphthyl
- defined above
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 23
- 238000002360 preparation method Methods 0.000 title claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 title description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 title description 2
- 150000003857 carboxamides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 98
- 239000000203 mixture Substances 0.000 claims description 27
- -1 methyl radicals Chemical class 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 150000003254 radicals Chemical class 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 10
- 230000027288 circadian rhythm Effects 0.000 claims description 10
- 230000001193 melatoninergic effect Effects 0.000 claims description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
- 229910052796 boron Inorganic materials 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 7
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000003610 charcoal Substances 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 208000019116 sleep disease Diseases 0.000 claims description 5
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 claims description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 4
- 208000012672 seasonal affective disease Diseases 0.000 claims description 4
- HTOLCOYGNDIFKC-UHFFFAOYSA-N 3-(4-methoxynaphthalen-1-yl)-n-methylpropanamide Chemical compound C1=CC=C2C(CCC(=O)NC)=CC=C(OC)C2=C1 HTOLCOYGNDIFKC-UHFFFAOYSA-N 0.000 claims description 3
- 208000027559 Appetite disease Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 claims description 2
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 claims description 2
- VJQJMZVPKOZTIO-UHFFFAOYSA-N 2-(7-methoxynaphthalen-1-yl)-n-methylacetamide Chemical compound C1=C(OC)C=C2C(CC(=O)NC)=CC=CC2=C1 VJQJMZVPKOZTIO-UHFFFAOYSA-N 0.000 claims description 2
- KMTWUHOZJCWVAW-UHFFFAOYSA-N 3-(7-methoxynaphthalen-1-yl)-n-methylpropanamide Chemical compound C1=C(OC)C=C2C(CCC(=O)NC)=CC=CC2=C1 KMTWUHOZJCWVAW-UHFFFAOYSA-N 0.000 claims description 2
- MJDVJPGPOXTVLS-UHFFFAOYSA-N 4-(7-methoxynaphthalen-1-yl)-n-propylbutanamide Chemical compound C1=C(OC)C=C2C(CCCC(=O)NCCC)=CC=CC2=C1 MJDVJPGPOXTVLS-UHFFFAOYSA-N 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000007280 thionation reaction Methods 0.000 claims description 2
- 230000017105 transposition Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 238000013459 approach Methods 0.000 description 15
- 238000012844 infrared spectroscopy analysis Methods 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 101150041968 CDC13 gene Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 230000033764 rhythmic process Effects 0.000 description 8
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 6
- 102000001419 Melatonin receptor Human genes 0.000 description 6
- 108050009605 Melatonin receptor Proteins 0.000 description 6
- 241001494479 Pecora Species 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 235000011148 calcium chloride Nutrition 0.000 description 5
- 238000000921 elemental analysis Methods 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 229960003987 melatonin Drugs 0.000 description 5
- 125000001624 naphthyl group Chemical group 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- FJDDSMSDZHURBJ-UHFFFAOYSA-N N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide Chemical compound COC1=CC=C2NC(I)=C(CCNC(C)=O)C2=C1 FJDDSMSDZHURBJ-UHFFFAOYSA-N 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000012173 estrus Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000006742 locomotor activity Effects 0.000 description 3
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 3
- 210000003101 oviduct Anatomy 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- PBULRPORNKTFNF-UHFFFAOYSA-N 3-(7-methoxynaphthalen-1-yl)propan-1-ol Chemical compound C1=CC=C(CCCO)C2=CC(OC)=CC=C21 PBULRPORNKTFNF-UHFFFAOYSA-N 0.000 description 2
- HBKGSOQMVORHIJ-UHFFFAOYSA-N 3-(7-methoxynaphthalen-1-yl)propanoic acid Chemical compound C1=CC=C(CCC(O)=O)C2=CC(OC)=CC=C21 HBKGSOQMVORHIJ-UHFFFAOYSA-N 0.000 description 2
- QGCVRUYJTZWBBX-UHFFFAOYSA-N 4-(7-methoxynaphthalen-1-yl)-n-methylbutanamide Chemical compound C1=C(OC)C=C2C(CCCC(=O)NC)=CC=CC2=C1 QGCVRUYJTZWBBX-UHFFFAOYSA-N 0.000 description 2
- AMPPAPAFNHIGGL-UHFFFAOYSA-N 4-(tert-butylamino)-2-(naphthalen-1-ylmethyl)-4-oxobutanoic acid Chemical compound C1=CC=C2C(CC(CC(=O)NC(C)(C)C)C(O)=O)=CC=CC2=C1 AMPPAPAFNHIGGL-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000002060 circadian Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000020335 dealkylation Effects 0.000 description 2
- 238000006900 dealkylation reaction Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000026234 pro-estrus Effects 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- XYAIEWYTPMDOKY-UHFFFAOYSA-N 2-(7-methoxynaphthalen-1-yl)-n-(2-methylpropyl)acetamide Chemical compound C1=CC=C(CC(=O)NCC(C)C)C2=CC(OC)=CC=C21 XYAIEWYTPMDOKY-UHFFFAOYSA-N 0.000 description 1
- PHUKAPAYOSDLEQ-UHFFFAOYSA-N 2-(7-methoxynaphthalen-1-yl)-n-pentylacetamide Chemical compound C1=C(OC)C=C2C(CC(=O)NCCCCC)=CC=CC2=C1 PHUKAPAYOSDLEQ-UHFFFAOYSA-N 0.000 description 1
- RSRSOQJDRNZZRH-UHFFFAOYSA-N 2-(7-methoxynaphthalen-1-yl)-n-propan-2-ylacetamide Chemical compound C1=CC=C(CC(=O)NC(C)C)C2=CC(OC)=CC=C21 RSRSOQJDRNZZRH-UHFFFAOYSA-N 0.000 description 1
- XFFVPOGFIFCJDX-UHFFFAOYSA-N 2-(7-methoxynaphthalen-1-yl)-n-propylacetamide Chemical compound C1=C(OC)C=C2C(CC(=O)NCCC)=CC=CC2=C1 XFFVPOGFIFCJDX-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- FKQNFZHHFSNRNM-UHFFFAOYSA-N 3-(5-ethoxy-1H-indol-3-yl)-N-methylpropanamide Chemical compound CCOC1=CC=C2NC=C(CCC(=O)NC)C2=C1 FKQNFZHHFSNRNM-UHFFFAOYSA-N 0.000 description 1
- YJWYKXPMFSRALF-UHFFFAOYSA-N 3-(5-ethoxy-1h-indol-3-yl)propanoic acid Chemical compound CCOC1=CC=C2NC=C(CCC(O)=O)C2=C1 YJWYKXPMFSRALF-UHFFFAOYSA-N 0.000 description 1
- FSJAQCYSHPRPBF-UHFFFAOYSA-N 3-(5-hydroxy-1-benzofuran-3-yl)-n-methylpropanamide Chemical compound C1=C(O)C=C2C(CCC(=O)NC)=COC2=C1 FSJAQCYSHPRPBF-UHFFFAOYSA-N 0.000 description 1
- QLXCHSMARQKROJ-UHFFFAOYSA-N 3-(5-hydroxy-1-benzofuran-3-yl)propanoic acid Chemical compound C1=C(O)C=C2C(CCC(=O)O)=COC2=C1 QLXCHSMARQKROJ-UHFFFAOYSA-N 0.000 description 1
- RAYQZJNZKYIKTO-UHFFFAOYSA-N 3-(5-phenylmethoxy-1-benzothiophen-3-yl)propanoic acid Chemical compound C1=C2C(CCC(=O)O)=CSC2=CC=C1OCC1=CC=CC=C1 RAYQZJNZKYIKTO-UHFFFAOYSA-N 0.000 description 1
- LQFHDXBJKLYZFD-UHFFFAOYSA-N 3-(6-methoxy-1-benzofuran-3-yl)-N-methylpropanamide Chemical compound CNC(=O)CCc1coc2cc(OC)ccc12 LQFHDXBJKLYZFD-UHFFFAOYSA-N 0.000 description 1
- GMJFYGULBCLUHD-UHFFFAOYSA-N 3-(6-methoxy-1-benzofuran-3-yl)propanoic acid Chemical compound COC1=CC=C2C(CCC(O)=O)=COC2=C1 GMJFYGULBCLUHD-UHFFFAOYSA-N 0.000 description 1
- LLCAIZDRONSEMH-UHFFFAOYSA-N 3-(7-methoxynaphthalen-1-yl)-n-(2-methylpropyl)propanamide Chemical compound C1=CC=C(CCC(=O)NCC(C)C)C2=CC(OC)=CC=C21 LLCAIZDRONSEMH-UHFFFAOYSA-N 0.000 description 1
- RAJYILJDFFJIAV-UHFFFAOYSA-N 3-(7-methoxynaphthalen-1-yl)-n-pentylpropanamide Chemical compound C1=C(OC)C=C2C(CCC(=O)NCCCCC)=CC=CC2=C1 RAJYILJDFFJIAV-UHFFFAOYSA-N 0.000 description 1
- LVNRNJOUORJPLO-UHFFFAOYSA-N 3-(7-methoxynaphthalen-1-yl)-n-propan-2-ylpropanamide Chemical compound C1=CC=C(CCC(=O)NC(C)C)C2=CC(OC)=CC=C21 LVNRNJOUORJPLO-UHFFFAOYSA-N 0.000 description 1
- VYVDTRQCFJGNAQ-UHFFFAOYSA-N 3-(7-methoxynaphthalen-1-yl)-n-propylpropanamide Chemical compound C1=C(OC)C=C2C(CCC(=O)NCCC)=CC=CC2=C1 VYVDTRQCFJGNAQ-UHFFFAOYSA-N 0.000 description 1
- MVLZUZCNZNMMOZ-UHFFFAOYSA-N 3-(7-methoxynaphthalen-1-yl)propanenitrile Chemical compound C1=CC=C(CCC#N)C2=CC(OC)=CC=C21 MVLZUZCNZNMMOZ-UHFFFAOYSA-N 0.000 description 1
- GBYKWWZSOGXRBJ-UHFFFAOYSA-N 3-(7-methoxynaphthalen-1-yl)propyl methanesulfonate Chemical compound C1=CC=C(CCCOS(C)(=O)=O)C2=CC(OC)=CC=C21 GBYKWWZSOGXRBJ-UHFFFAOYSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- PITLVAVQHVNHFL-UHFFFAOYSA-N 4-(4,6-dimethoxy-1h-indol-3-yl)-n-methylbutanamide Chemical compound COC1=CC(OC)=C2C(CCCC(=O)NC)=CNC2=C1 PITLVAVQHVNHFL-UHFFFAOYSA-N 0.000 description 1
- GXNGEKHOYKEIFP-UHFFFAOYSA-N 4-(4,6-dimethoxy-1h-indol-3-yl)butanoic acid Chemical compound COC1=CC(OC)=C2C(CCCC(O)=O)=CNC2=C1 GXNGEKHOYKEIFP-UHFFFAOYSA-N 0.000 description 1
- PHWKGWFNQVQFGG-UHFFFAOYSA-N 4-(5-fluoro-1h-indol-3-yl)-n-methylbutanamide Chemical compound C1=C(F)C=C2C(CCCC(=O)NC)=CNC2=C1 PHWKGWFNQVQFGG-UHFFFAOYSA-N 0.000 description 1
- IJAVCLNGRFTCBG-UHFFFAOYSA-N 4-(5-fluoro-1h-indol-3-yl)butanoic acid Chemical compound C1=C(F)C=C2C(CCCC(=O)O)=CNC2=C1 IJAVCLNGRFTCBG-UHFFFAOYSA-N 0.000 description 1
- GAGOWEHXCKRCLY-UHFFFAOYSA-N 4-(5-methoxy-1-benzofuran-3-yl)-n-methylbutanamide Chemical compound C1=C(OC)C=C2C(CCCC(=O)NC)=COC2=C1 GAGOWEHXCKRCLY-UHFFFAOYSA-N 0.000 description 1
- RZJOGMVLRNRGSN-UHFFFAOYSA-N 4-(5-methoxy-1-benzofuran-3-yl)butanoic acid Chemical compound COC1=CC=C2OC=C(CCCC(O)=O)C2=C1 RZJOGMVLRNRGSN-UHFFFAOYSA-N 0.000 description 1
- LPRAOPFVIPATTN-UHFFFAOYSA-N 4-(6-methoxy-1h-indol-3-yl)-n-methylbutanamide Chemical compound COC1=CC=C2C(CCCC(=O)NC)=CNC2=C1 LPRAOPFVIPATTN-UHFFFAOYSA-N 0.000 description 1
- UVSKMUUZNSCQKR-UHFFFAOYSA-N 4-(6-methoxy-1h-indol-3-yl)butanoic acid Chemical compound COC1=CC=C2C(CCCC(O)=O)=CNC2=C1 UVSKMUUZNSCQKR-UHFFFAOYSA-N 0.000 description 1
- JHSWNUDBSFLIQF-UHFFFAOYSA-N 4-(7-hydroxynaphthalen-1-yl)-n-methylbutanamide Chemical compound C1=C(O)C=C2C(CCCC(=O)NC)=CC=CC2=C1 JHSWNUDBSFLIQF-UHFFFAOYSA-N 0.000 description 1
- NXMJQNPYDGDKSK-UHFFFAOYSA-N 4-(7-methoxynaphthalen-1-yl)-n-(2-methylpropyl)butanamide Chemical compound C1=CC=C(CCCC(=O)NCC(C)C)C2=CC(OC)=CC=C21 NXMJQNPYDGDKSK-UHFFFAOYSA-N 0.000 description 1
- FCXQQOBYMLCNAW-UHFFFAOYSA-N 4-(7-methoxynaphthalen-1-yl)-n-pentylbutanamide Chemical compound C1=C(OC)C=C2C(CCCC(=O)NCCCCC)=CC=CC2=C1 FCXQQOBYMLCNAW-UHFFFAOYSA-N 0.000 description 1
- RSXMYMSFUVNYDW-UHFFFAOYSA-N 4-(7-methoxynaphthalen-1-yl)-n-propan-2-ylbutanamide Chemical compound C1=CC=C(CCCC(=O)NC(C)C)C2=CC(OC)=CC=C21 RSXMYMSFUVNYDW-UHFFFAOYSA-N 0.000 description 1
- ROOITFNWOBPSOU-UHFFFAOYSA-N 4-(7-methoxynaphthalen-1-yl)butanoic acid Chemical compound C1=CC=C(CCCC(O)=O)C2=CC(OC)=CC=C21 ROOITFNWOBPSOU-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- NSQFXGIROIHQAU-UHFFFAOYSA-N N-methyl-3-(5-propyl-1H-indol-3-yl)propanamide Chemical compound CCCC1=CC=C2NC=C(CCC(=O)NC)C2=C1 NSQFXGIROIHQAU-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 238000006434 Ritter amidation reaction Methods 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001966 cerebroprotective effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008632 circadian clock Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000027046 diestrus Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- SMRZQXAGZRXPNH-UHFFFAOYSA-N methyl 3-(7-methoxynaphthalen-1-yl)propanoate Chemical compound C1=C(OC)C=C2C(CCC(=O)OC)=CC=CC2=C1 SMRZQXAGZRXPNH-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XPIYFPIKIWHZAJ-UHFFFAOYSA-N n-butyl-2-(7-methoxynaphthalen-1-yl)acetamide Chemical compound C1=C(OC)C=C2C(CC(=O)NCCCC)=CC=CC2=C1 XPIYFPIKIWHZAJ-UHFFFAOYSA-N 0.000 description 1
- XJRBPPZLDXVBKC-UHFFFAOYSA-N n-butyl-3-(7-methoxynaphthalen-1-yl)propanamide Chemical compound C1=C(OC)C=C2C(CCC(=O)NCCCC)=CC=CC2=C1 XJRBPPZLDXVBKC-UHFFFAOYSA-N 0.000 description 1
- PZBGWHCCJMMUPE-UHFFFAOYSA-N n-butyl-4-(7-methoxynaphthalen-1-yl)butanamide Chemical compound C1=C(OC)C=C2C(CCCC(=O)NCCCC)=CC=CC2=C1 PZBGWHCCJMMUPE-UHFFFAOYSA-N 0.000 description 1
- ZFEQPJHCLUCSKH-UHFFFAOYSA-N n-ethyl-2-(7-methoxynaphthalen-1-yl)acetamide Chemical compound C1=C(OC)C=C2C(CC(=O)NCC)=CC=CC2=C1 ZFEQPJHCLUCSKH-UHFFFAOYSA-N 0.000 description 1
- ZJIYXVZOEBWWBW-UHFFFAOYSA-N n-ethyl-3-(7-methoxynaphthalen-1-yl)propanamide Chemical compound C1=C(OC)C=C2C(CCC(=O)NCC)=CC=CC2=C1 ZJIYXVZOEBWWBW-UHFFFAOYSA-N 0.000 description 1
- QYHBMAUHKYHCCT-UHFFFAOYSA-N n-ethyl-4-(7-methoxynaphthalen-1-yl)butanamide Chemical compound C1=C(OC)C=C2C(CCCC(=O)NCC)=CC=CC2=C1 QYHBMAUHKYHCCT-UHFFFAOYSA-N 0.000 description 1
- RTIDGDQPMKPQPX-UHFFFAOYSA-N n-hexyl-2-(7-methoxynaphthalen-1-yl)acetamide Chemical compound C1=C(OC)C=C2C(CC(=O)NCCCCCC)=CC=CC2=C1 RTIDGDQPMKPQPX-UHFFFAOYSA-N 0.000 description 1
- DSHUZGOHCRFQOP-UHFFFAOYSA-N n-hexyl-3-(7-methoxynaphthalen-1-yl)propanamide Chemical compound C1=C(OC)C=C2C(CCC(=O)NCCCCCC)=CC=CC2=C1 DSHUZGOHCRFQOP-UHFFFAOYSA-N 0.000 description 1
- FRZAVDGRZJANBU-UHFFFAOYSA-N n-hexyl-4-(7-methoxynaphthalen-1-yl)butanamide Chemical compound C1=C(OC)C=C2C(CCCC(=O)NCCCCCC)=CC=CC2=C1 FRZAVDGRZJANBU-UHFFFAOYSA-N 0.000 description 1
- RYJQAVXZYQMDFI-UHFFFAOYSA-N n-methyl-3-(5-methyl-1-benzothiophen-3-yl)propanamide Chemical compound C1=C(C)C=C2C(CCC(=O)NC)=CSC2=C1 RYJQAVXZYQMDFI-UHFFFAOYSA-N 0.000 description 1
- CDFBYQKPYJKOHH-UHFFFAOYSA-N n-methyl-4-(7-propoxynaphthalen-1-yl)butanamide Chemical compound C1=CC=C(CCCC(=O)NC)C2=CC(OCCC)=CC=C21 CDFBYQKPYJKOHH-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- DDMGAAYEUNWXSI-XVSDJDOKSA-M sodium;(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound [Na+].CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O DDMGAAYEUNWXSI-XVSDJDOKSA-M 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Pyrane Compounds (AREA)
- Furan Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9506435A FR2734815B1 (fr) | 1995-05-31 | 1995-05-31 | Nouveaux composes arylalkyl (thio) carboxamides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO962208D0 NO962208D0 (no) | 1996-05-30 |
| NO962208L NO962208L (no) | 1996-12-02 |
| NO310653B1 true NO310653B1 (no) | 2001-08-06 |
Family
ID=9479525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19962208A NO310653B1 (no) | 1995-05-31 | 1996-05-30 | Nye arylalkyl(tio)karboksamider, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5721276A (da) |
| EP (1) | EP0745584B1 (da) |
| JP (1) | JPH08337564A (da) |
| CN (1) | CN1059433C (da) |
| AT (1) | ATE188465T1 (da) |
| AU (1) | AU703998B2 (da) |
| CA (1) | CA2177780C (da) |
| DE (1) | DE69605975T2 (da) |
| DK (1) | DK0745584T3 (da) |
| ES (1) | ES2143729T3 (da) |
| FR (1) | FR2734815B1 (da) |
| GR (1) | GR3032402T3 (da) |
| NO (1) | NO310653B1 (da) |
| NZ (1) | NZ286697A (da) |
| PT (1) | PT745584E (da) |
| ZA (1) | ZA964478B (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2763335B1 (fr) * | 1997-05-16 | 2000-11-24 | Adir | Nouveaux composes heterocycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2771739B1 (fr) * | 1997-11-28 | 2001-04-20 | Adir | Nouveaux composes naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2773798B1 (fr) | 1998-01-16 | 2001-02-02 | Adir | Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2778662B1 (fr) * | 1998-05-12 | 2000-06-16 | Adir | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2784375B1 (fr) * | 1998-10-12 | 2000-11-24 | Adir | Nouveaux derives cycliques a chaine cycloalkylenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2857010B1 (fr) * | 2003-07-01 | 2005-09-16 | Servier Lab | Nouveaux derives bicycliques alkyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20070105937A1 (en) * | 2003-12-22 | 2007-05-10 | Miguel Pappolla | Indole-3-propionamide and derivatives thereof |
| WO2020159576A1 (en) | 2019-01-28 | 2020-08-06 | Mitochondria Emotion, Inc. | Mitofusin activators and methods of use thereof |
| EP3917509A4 (en) | 2019-01-28 | 2022-11-09 | Mitochondria Emotion, Inc. | ACTIVATORS OF TRANS-4-HYDROXYCYCLOHEXYLPHENYLAMIDE DERIVATIVES OF MITOFUSIN AND METHODS OF USE THEREOF |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751306A (en) * | 1985-09-09 | 1988-06-14 | E. I. Du Pont De Nemours And Company | Imide intermediates for the preparation of analgesic and/or antagonist octahydrobenzofuroisoquinolines |
| JPH0686422B2 (ja) * | 1989-06-28 | 1994-11-02 | 株式会社トクヤマ | Ｎ‐置換ジカルボン酸イミド化合物の製造方法 |
| EP0427939A3 (en) * | 1989-10-11 | 1991-11-06 | American Cyanamid Company | Renin inhibitors |
| FR2658818B1 (fr) * | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| JP2985392B2 (ja) * | 1991-08-06 | 1999-11-29 | 住友化学工業株式会社 | ゴム組成物 |
| FR2680366B1 (fr) * | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2680507B1 (fr) * | 1991-08-23 | 1993-10-08 | Adir Cie | Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2713636B1 (fr) * | 1993-12-07 | 1996-01-05 | Adir | Nouveaux dérivés naphtaléniques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent. |
| US5753700A (en) * | 1994-12-28 | 1998-05-19 | Ono Pharmaceutical Co., Ltd. | Naphthyloxyacetic acid derivatives |
-
1995
- 1995-05-31 FR FR9506435A patent/FR2734815B1/fr not_active Expired - Lifetime
-
1996
- 1996-05-29 JP JP8134736A patent/JPH08337564A/ja active Pending
- 1996-05-29 AU AU54560/96A patent/AU703998B2/en not_active Ceased
- 1996-05-30 DE DE69605975T patent/DE69605975T2/de not_active Expired - Fee Related
- 1996-05-30 NO NO19962208A patent/NO310653B1/no not_active Application Discontinuation
- 1996-05-30 EP EP96401159A patent/EP0745584B1/fr not_active Expired - Lifetime
- 1996-05-30 NZ NZ286697A patent/NZ286697A/en unknown
- 1996-05-30 CA CA002177780A patent/CA2177780C/fr not_active Expired - Fee Related
- 1996-05-30 DK DK96401159T patent/DK0745584T3/da active
- 1996-05-30 ES ES96401159T patent/ES2143729T3/es not_active Expired - Lifetime
- 1996-05-30 CN CN96107791A patent/CN1059433C/zh not_active Expired - Fee Related
- 1996-05-30 AT AT96401159T patent/ATE188465T1/de not_active IP Right Cessation
- 1996-05-30 PT PT96401159T patent/PT745584E/pt unknown
- 1996-05-30 US US08/657,972 patent/US5721276A/en not_active Expired - Fee Related
- 1996-05-31 ZA ZA964478A patent/ZA964478B/xx unknown
-
2000
- 2000-01-18 GR GR20000400096T patent/GR3032402T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PT745584E (pt) | 2000-04-28 |
| DK0745584T3 (da) | 2000-06-26 |
| ATE188465T1 (de) | 2000-01-15 |
| AU703998B2 (en) | 1999-04-01 |
| ZA964478B (en) | 1997-03-11 |
| DE69605975D1 (de) | 2000-02-10 |
| NO962208L (no) | 1996-12-02 |
| NO962208D0 (no) | 1996-05-30 |
| CA2177780C (fr) | 1999-11-09 |
| NZ286697A (en) | 1998-03-25 |
| EP0745584B1 (fr) | 2000-01-05 |
| ES2143729T3 (es) | 2000-05-16 |
| JPH08337564A (ja) | 1996-12-24 |
| FR2734815A1 (fr) | 1996-12-06 |
| CA2177780A1 (fr) | 1996-12-01 |
| CN1059433C (zh) | 2000-12-13 |
| EP0745584A1 (fr) | 1996-12-04 |
| CN1145894A (zh) | 1997-03-26 |
| DE69605975T2 (de) | 2000-08-17 |
| GR3032402T3 (en) | 2000-05-31 |
| AU5456096A (en) | 1996-12-12 |
| FR2734815B1 (fr) | 1997-07-04 |
| US5721276A (en) | 1998-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5308866A (en) | Benzofuran ethylamine compounds | |
| US5760071A (en) | Aryl(alkyl)propylamides | |
| US5843986A (en) | Tricyclic amide compounds | |
| US5668180A (en) | Alkoxyaryl compounds | |
| US5780512A (en) | Alkylated (hetero) cyclic compounds | |
| NO310653B1 (no) | Nye arylalkyl(tio)karboksamider, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem | |
| US5919814A (en) | Heterocyclic compounds | |
| NO324562B1 (no) | Nye substituerte heterocykliske forbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| NO327076B1 (no) | Nye cykliske forbindelser som har en cykloalkylenkjede, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| AU737475B2 (en) | New heterocyclic compounds, a process for their preparation and pharmaceutical compositions containing them | |
| US5612368A (en) | O-arylmethyl-N-(thio)acylhydroxylamines | |
| US5998461A (en) | Tricyclic amide compounds | |
| US6071946A (en) | Tricyclic urea compounds | |
| US5948817A (en) | Polycyclic ethyl alkylamide melatonergic agents | |
| ZA200301351B (en) | Substituted Biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same. | |
| MXPA05004910A (es) | Nuevos derivados de fenilnaftaleno, metodo para su produccion y composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |